Author Correction: Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid in vitro.
Author Correction: Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid in vitro. Acta Pharmacol Sin. 2019 May 16;: Authors: Qiao H, Wang TY, Yan W, Qin A, Fan QM, Han XG, Wang YG, Tang TT Abstract The authors regretted to find the mis-representative images in Fig. 3a, c and Fig. 4a, c when re-read our previously published article Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro (DOI: 10.1038/aps.2015.42) in the journal of Acta Pharmacologica Sinica. This mistake occurred due to the careless compilation when the authors tried to show the synergistic effect against tumor apoptosis during figure presentation process. The right Fig. 3a, c and Fig. 4a, c were provided below. Despite that this correction does not affect the results and conclusions of the aforementioned paper, all the authors still consent on the correction of this negligence. We apologize to the Editor and the readership of the journal for any inconvenience caused. Your thoughtful understanding is highly appreciated. PMID: 31097762 [PubMed - as supplied by publisher]
Abstract In cancer diagnostics, specific analysis of blood-circulating proteins biomarkers of cancer is often complicated both by their inherently low concentrations and by strong interference from serum/blood proteins. Here, we report a simple and robust electrochemical cellulase-linked sandwich assay on magnetic beads (MBs) for fM-sensitive analysis of the Human Epidermal growth factor Receptor-2 HER-2/neu protein that is over-expressed in most aggressive breast cancers. In the assay, a sandwich is assembled by capturing HER-2/neu on either antibody (Ab) or aptamer-modified MBs accompanied by reaction with the s...
Darla Jaye, from The Woodlands, Texas, was diagnosed with breast cancer in February. She finished her final radiation treatment at Harris Health Systems on Monday, July 15.
ConclusionsTailoring radiation therapy to clinical risk factors was associated with excellent locoregional control. De-escalation of PMRT from BID to QD was not clearly associated with reduced toxicity compared with BID, although retrospective data collection may limit this comparison.
In conclusion, Denosumab administration can be considered effective and safe in the prevention and management of the above mentioned adverse events related to hormonal therapies designed for breast and prostate tumors.
Condition: Breast Neoplasms Intervention: Drug: Endocrine therapy Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting
Conditions: Cardiotoxicity; Risk Factor, Cardiovascular; Toxicity Due to Chemotherapy; Breast Cancer; Cardiomyopathies; Heart Failure Intervention: Drug: Carvedilol Sponsor: Abramson Cancer Center of the University of Pennsylvania Not yet recruiting
Condition: Breast Carcinoma Interventions: Other: Best Practice; Other: Medical Chart Review; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Procedure: Supportive Care Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI); Genentech, Inc. Not yet recruiting
Condition: Breast Cancer Intervention: Other: Specimen collection Sponsors: Ohio State University Comprehensive Cancer Center; National Cancer Institute (NCI) Recruiting
Publication date: 16 July 2019Source: Cell Reports, Volume 28, Issue 3Author(s): Pavel Bouchal, Olga T. Schubert, Jakub Faktor, Lenka Capkova, Hana Imrichova, Karolina Zoufalova, Vendula Paralova, Roman Hrstka, Yansheng Liu, Holger Alexander Ebhardt, Eva Budinska, Rudolf Nenutil, Ruedi AebersoldSummaryAccurate classification of breast tumors is vital for patient management decisions and enables more precise cancer treatment. Here, we present a quantitative proteotyping approach based on sequential windowed acquisition of all theoretical fragment ion spectra (SWATH) mass spectrometry and establish key proteins for breast tu...